Stock Track | HENLIUS Soars 10.81% on Deal with Dr. Reddy's Labs for Myeloma Drug-To The Moon - Tiger Brokers Online Investing Community

Like
Comment
Favorite

Stock Track | HENLIUS Soars 10.81% on Deal with Dr. Reddy's Labs for Myeloma Drug

Stock Track02-07

Shares of HENLIUS (02696.HK) surged 10.81% during the intraday trading session on Friday, following news of a licensing deal with India-based pharmaceutical company Dr. Reddy's Laboratories (REDY.NS) for its myeloma drug HLX15.

Under the agreement, HENLIUS will grant Dr. Reddy's the license to develop, manufacture, and commercialize HLX15 in the United States, United Kingdom, Switzerland, and 42 other European countries. Dr. Reddy's will pay an upfront payment of $33 million, milestone payments of up to $98.6 million, and royalties of up to 8% of annual net sales to HENLIUS.

HLX15 is a biopharmaceutical product used for the treatment of multiple myeloma, a type of blood cancer. The deal represents a significant step in HENLIUS's expansion into overseas markets and reflects the growing demand for innovative cancer treatments globally.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

抱歉，当前请求异常(-1)

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1104723932?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-02-07 14:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1104723932","market":"us","top_or_hot":-1,"title":"Stock Track | HENLIUS Soars 10.81% on Deal with Dr. Reddy's Labs for Myeloma Drug","media":"Stock Track","content":"<p>Shares of HENLIUS (02696.HK) surged 10.81% during the intraday trading session on Friday, following news of a licensing deal with India-based pharmaceutical company Dr. Reddy's Laboratories (REDY.NS) for its myeloma drug HLX15.</p>\n\n<p>Under the agreement, HENLIUS will grant Dr. Reddy's the license to develop, manufacture, and commercialize HLX15 in the United States, United Kingdom, Switzerland, and 42 other European countries. Dr. Reddy's will pay an upfront payment of $33 million, milestone payments of up to $98.6 million, and royalties of up to 8% of annual net sales to HENLIUS.</p>\n\n<p>HLX15 is a biopharmaceutical product used for the treatment of multiple myeloma, a type of blood cancer. The deal represents a significant step in HENLIUS's expansion into overseas markets and reflects the growing demand for innovative cancer treatments globally.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | HENLIUS Soars 10.81% on Deal with Dr. Reddy's Labs for Myeloma Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | HENLIUS Soars 10.81% on Deal with Dr. Reddy's Labs for Myeloma Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-07 14:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of HENLIUS (02696.HK) surged 10.81% during the intraday trading session on Friday, following news of a licensing deal with India-based pharmaceutical company Dr. Reddy's Laboratories (REDY.NS) for its myeloma drug HLX15.</p>\n\n<p>Under the agreement, HENLIUS will grant Dr. Reddy's the license to develop, manufacture, and commercialize HLX15 in the United States, United Kingdom, Switzerland, and 42 other European countries. Dr. Reddy's will pay an upfront payment of $33 million, milestone payments of up to $98.6 million, and royalties of up to 8% of annual net sales to HENLIUS.</p>\n\n<p>HLX15 is a biopharmaceutical product used for the treatment of multiple myeloma, a type of blood cancer. The deal represents a significant step in HENLIUS's expansion into overseas markets and reflects the growing demand for innovative cancer treatments globally.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02696","symbol_name":"复宏汉霖","start_time":0,"source_url":"","article_id":"1104723932","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1104723932","pubTimestamp":1738908406,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of HENLIUS  surged 10.81% during the intraday trading session on Friday, following news of a licensing deal with India-based pharmaceutical company Dr. Reddy's Laboratories  for its myeloma drug HLX15.Under the agreement, HENLIUS will grant Dr. Reddy's the license to develop, manufacture, and commercialize HLX15 in the United States, United Kingdom, Switzerland, and 42 other European countries. Dr. Reddy's will pay an upfront payment of $33 million, milestone payments of up to $98.6 milli","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02696":"复宏汉霖"},"translate_title":"与Dr.Reddy's Labs达成骨髓瘤药物交易，股价飙升10.81%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02696":1},"content_text":"Shares of HENLIUS (02696.HK) surged 10.81% during the intraday trading session on Friday, following news of a licensing deal with India-based pharmaceutical company Dr. Reddy's Laboratories (REDY.NS) for its myeloma drug HLX15.\nUnder the agreement, HENLIUS will grant Dr. Reddy's the license to develop, manufacture, and commercialize HLX15 in the United States, United Kingdom, Switzerland, and 42 other European countries. Dr. Reddy's will pay an upfront payment of $33 million, milestone payments of up to $98.6 million, and royalties of up to 8% of annual net sales to HENLIUS.\nHLX15 is a biopharmaceutical product used for the treatment of multiple myeloma, a type of blood cancer. The deal represents a significant step in HENLIUS's expansion into overseas markets and reflects the growing demand for innovative cancer treatments globally.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}